ArticleTheranostics2017
Synthesis of 5-[
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.Molecular imaging and biology · 2020Pooled it
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside.Biomolecules · 2025Review
- SyntheticRSC medicinal chemistry · 2024Review
- Automated radiosynthesis of 1-(2-[Journal of labelled compounds & radiopharmaceuticals · 2023Article
- Development of [Journal of medicinal chemistry · 2023Article
- Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.Oncoimmunology · 2023Article
- Recent Advances inPharmaceutics · 2022Review
- Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy.Journal for immunotherapy of cancer · 2021Article
- Copper-Mediated Late-stage Radiofluorination: Five Years of Impact on Pre-clinical and Clinical PET Imaging.Clinical and translational imaging · 2020Article
- Boron Accumulation in Brain Tumor Cells through Boc-Protected Tryptophan as a Carrier for Boron Neutron Capture Therapy.ACS medicinal chemistry letters · 2020Article
- Utility of MRI, PET, and ictal SPECT in presurgical evaluation of non-lesional pediatric epilepsy.Seizure · 2020Review
- PET imaging of medulloblastoma with anScientific reports · 2020Article
- The therapeutic potential of targeting tryptophan catabolism in cancer.British journal of cancer · 2020Review
- Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin.Molecules (Basel, Switzerland) · 2019Article
- Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer.EJNMMI radiopharmacy and chemistry · 2019Review
- Synthesis and initial evaluation of radioactive 5-I-α-methyl-tryptophan: a Trp based agent targeting IDO-1.MedChemComm · 2019Article
- MCR Scaffolds Get Hotter withMolecules (Basel, Switzerland) · 2019Article
- HydrophilicChemical communications (Cambridge, England) · 2019Article
- Advances in Engineering Cells for Cancer Immunotherapy.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Indoleamine 2,3-dioxygenase (IDO1) plays a special role in the biology of various cancer types, because it breaks down the essential amino acid tryptophan for immune cell activation. Upregulation of IDO1 significantly correlates with the number of various T cell types in tumor tissues in melanoma and other cancers, suggesting that IDO expression is linked with effective and ineffective ('exhausted') immune response in cancer. Based on the reported IDO inhibitors (α-Methylated and indole-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.